NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio
April 08, 2022 08:00 ET
|
NGM Biopharmaceuticals, Inc.
ILT2, ILT4, ILT3 and LAIR1 are myeloid checkpoints that may play a central role in establishing an immune-suppressive state in the tumor microenvironmentNGM707, NGM831 and NGM438 are all engineered to...
NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors
March 31, 2022 16:05 ET
|
NGM Biopharmaceuticals, Inc.
Dose-escalation and dose-expansion trial evaluating potential of NGM831, an ILT3 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) initiated and...
NGM Bio to Host the First of Four Virtual R&D Events on March 30, 2022
March 21, 2022 08:00 ET
|
NGM Biopharmaceuticals, Inc.
--The four-part series titled the “Explorer Series” will showcase NGM Bio’s discovery engine, myeloid reprogramming and checkpoint inhibition portfolio and program for the treatment of geographic...
NGM Bio Announces Oral and Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio at Upcoming 2022 AACR Annual Meeting
March 08, 2022 16:13 ET
|
NGM Biopharmaceuticals, Inc.
Oral presentation to showcase NGM Bio’s in vitro and in vivo research demonstrating potential advantages of dual ILT2/ILT4 inhibition with NGM707, currently in Phase 1/2 trialLate-breaking poster...
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
March 01, 2022 16:06 ET
|
NGM Biopharmaceuticals, Inc.
Advanced programs across NGM Bio’s pipeline in retinal diseases, oncology and liver and metabolic diseases during the fourth quarter and beginning of 2022: Obtained Fast Track designation from the...
NGM Bio to Participate in the Cowen 42nd Annual Health Care Conference
February 28, 2022 08:00 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
February 07, 2022 08:00 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
NGM Bio to Participate in Upcoming Investor Conferences
January 20, 2022 08:00 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
NGM Bio Outlines 2022 Strategic Priorities Across Its Portfolio of Clinical-Stage Oncology, Retinal and Liver and Metabolic Programs
January 10, 2022 09:00 ET
|
NGM Biopharmaceuticals, Inc.
After a transformative year in 2021, NGM Bio enters 2022 with a diverse pipeline of seven disclosed programs, including four programs in Phase 2 trials and a wholly-owned oncology portfolioAnticipated...
NGM Bio to Present at 40th Annual J.P. Morgan Healthcare Conference
January 06, 2022 08:00 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...